Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9822-353256      Publish Date : Monday, August 7, 2017 Visit : 2431

Intl. Congress form | International Congress Report | International Congress Report For Students and Staff | ESMO Asia 2016 by Manijeh Beigi

ESMO Asia 2016 by Manijeh Beigi
ESMO Asia 2016 by Manijeh Beigi
Application Code :
762-0117-0002
 
Created Date : Monday, April 10, 2017-12:09 12:09:09Update Date : Saturday, July 15, 2017-14:52 14:52:38
IP Address : 77.104.103.244Submit Date : Saturday, July 15, 2017-14:52 14:52:58Email : beigi310@gmail.com
Personal Information
Name : Manijeh
Surname : Beigi
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Position : student
Tel : +98-21-44608339
Information of Congress
Title of the Congress : ESMO Asia 2016
Title of your Abstract : Heterogeneity Analysis of DW MRI as a Biomarker for Prediction of Overall Survival and 6month PFS in GBM Patients
Destination Country : Singapore
From : Friday, December 16, 2016
To : Monday, December 19, 2016
Abstract(Please copy/paste the abstract send to the congress) : Background: GBM is the primary malignant brain tumors with median patient’s survival of 12-15 months. Different treatment responses of GBM related to intra-tumoral heterogeneity causes to variable behavior and clinical symptoms of tumor. Anatomical MRI are not capable of providing information about tumor matrix. Diffusion-weighted (DW) MRI provide physiological information about tumor cellularity by quantifying the water diffusivity within tumor. The purpose of this study is to evaluate the use of texture analysis of DWI for pretreatment prediction of overall and 6-month progression free survival in patients with GBM. br/Method and material: 11 patients with GBM who were referred to Jorjani Center between 2012 and 2014 (Table1), were selected. All patients gave their written informed consent before their participation. Conventional and DW MRI were carried out at 1.5 T MRI before treatment. Apparent diffusion coefficient (ADC) maps were generated from DW images on the system workstation. T2 FLAIR images were registered to ADC map for each patients. ROI was placed on tumor region in T2FLAIR images by. The ROI’s masks were transferred to in-house programs in MATLAB V.7.12 (Figure1). The heterogeneity of the tumor were explored by first-order histogram of ADC included: 1) histogram standard deviation 2) smoothness, 3) third moment, 4) uniformity, 5) entropy, 6) kurtosis 7) Percentile25, 8) Percentile75 and 9) Percentile95. br/Results: Positive correlation was seen between Percentile25, Percentile75 and Percentile95 with overall survival that were statistically significant (p0.05): p=0.047, p=0.041 and p=0.01 respectively. 6-month progression free survival of patients were acquired using follow up MRI and best pretreatment parameters to classify patients with 6-month PFS from patients without PFS were acquired using discriminant analysis. Of all the parameters, percentile25 is the best parameter to discriminate two groups (Wilks’ lambda=0.702).br/Discussion: Quantitative heterogeneity metrics of DW imaging were explored to obtain the most accurate metrics as potential predictive biomarker for theraputic outcome. The positive correlation of above mentioned parameters implies that tumors with higher three metrics will respond better to therapy and longer overall survival. These results demonstrate the feasibility of applying heterogeneity analysis of DW MRI for pre-treatment prediction of survival in GBM patients undergoing radiation therapy. The results reported in this abstract will be validated in twenty eight population to determine which heterogeneity metrics can be adopted as relevant biomarkers for outcome prediction of GBM. br/br/
Keywords of your Abstract : DW MRI, Radiotherapy, Glioblastoma
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/34296/Forms/762/acceptance_letter_1_.pdf
The presentation : Poster
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/34296/Forms/762/cover_book_1_.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/34296/Forms/762/abstract__esmo_1_.pdf
Where has your abstract been indexed? : none
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : About 2000 volunteers
Delegates from which countries presented in the congress? : Asian Countries, European Countries, American countries
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : Iranian Cancer Association, European Society of Radiotherapy and oncology, Chinese Anti-Cancer Association, American Society for Radiation Oncology , Indian Caner Society
What were the responses to your talking points? Were specific questions or concerns raised? : The most important point of my abstract was correlation of imaging parameters with patients survival. one of the question was about the way of quantitative parameters extraction from DW MRI
If you met staff members, please list their full names & positions. : I didn't meet staff member.
Please inform us if there are any follow up actions we need to talk with the members of the congress :  
Your experiences about the travel processes(Providing ticket, accommodation,...) : Providing ticket and accommodation were easy. Some hotels were dedicated for participants for three nights. There was transport system especially for conference participants from hotel to place of conference.
Please give a briefing of your own observations and outcomes of the congress: : The second ESMO Asia Congress took place in Singapore 16-19 December 2016. This scientific and educational congress was led by an international scientific committee and promoted the sharing of expertise and interaction between regional and international experts in oncology. The programme offered state of the art science and the current standard across all major tumour types.